<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92228">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01669954</url>
  </required_header>
  <id_info>
    <org_study_id>RJ1 09/0329</org_study_id>
    <secondary_id>08/H0805/56</secondary_id>
    <nct_id>NCT01669954</nct_id>
  </id_info>
  <brief_title>Determination of Optimum Age for DXA Screening for Osteoporosis in HIV - The Probono 1 Study</brief_title>
  <acronym>Probono1</acronym>
  <official_title>Prospective Study to Determine the Optimum Age for Routine DEXA Screening for Osteopenia/Osteoporosis in People With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St Thomas' Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bone mineral density in male and female
      patients with HIV infection according to age groups.

      This will enable a practical approach to screening for osteoporosis and the management and
      prevention of fragility fractures in people with HIV.

      In addition, all risk factors commonly associated with fragility fractures and osteoporosis
      are collected, as is HIV drug history.

      Hence, as secondary outcomes, the associations with reduced bone mineral density can be
      ascertained.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Bone mineral density at Hip</measure>
    <time_frame>The outcome is measured within 6 months (0-6 months) after entry to the study.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bone mineral density as determined by DXA scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density at spine (L4)</measure>
    <time_frame>The outcome is measured within 6 months (0-6 months) after entry to the study.</time_frame>
    <safety_issue>No</safety_issue>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any lifetime fractures reported by subjects</measure>
    <time_frame>At any stage during persons life up to and including the last visit for the volunteer to the study.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported fractures of any type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D levels</measure>
    <time_frame>The outcome is measured within 6 months (0-6 months) after entry to the study.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma vitamin D</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">440</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Fractures</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Controls, females</arm_group_label>
    <description>Controls who are presumed HIV uninfected, females, aged 18 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls, males</arm_group_label>
    <description>Controls presumed HIV uninfected, males, aged 18 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV infected patients, males</arm_group_label>
    <description>HIV patients, males, aged 18 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV patients,</arm_group_label>
    <description>HIV patients, females, aged 18 or above</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A randomly recruited numbers of HIV uninfected controls and HIV patients aged 18 years or
        above, equally matched for age, and gender.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or above Not pregnant Able to comply with study observations and procedures
             Able to give fully informed consent

        Exclusion Criteria:

          -  Pregnant Less than 18 years of age Unable to comply with study procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry S Peters, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Thomas, Hospital</name>
      <address>
        <city>London</city>
        <zip>SE30AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 17, 2012</lastchanged_date>
  <firstreceived_date>August 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Barry Stephen Peters</investigator_full_name>
    <investigator_title>Reader and Consultant HIV Medicine, Head of Research Unit, Principle Investigator, Clinical Researcher</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Fractures</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
